Page 110 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Alpha-2A receptor agonist and addiction

Malik MN. Clinical efficacy and safety profile of lofexidine perspective: Dopamine homeostasis. J Am Osteopath Assoc.
hydrochloride in treating opioid withdrawal symptoms: 2018;118(2):115-118.
A review of literature. Cureus. 2019;11(6):e4827.
doi: 10.7556/jaoa.2018.026
doi: 10.7759/cureus.4827
75. Febo M, Blum K, Badgaiyan RD, et al. Enhanced functional
65. Blum K, Badgaiyan RD, Braverman ER, et al. Hypothesizing connectivity and volume between cognitive and reward
that, a pro-dopamine regulator (KB220Z) should optimize, centers of naïve rodent brain produced by pro-dopaminergic
but not hyper-activate the activity of trace amine- agent KB220Z. PLoS One. 2017;12(4):e0174774.
associated receptor 1 (TAAR-1) and induce anti-craving of
psychostimulants in the long-term. J Reward Defic Syndr doi: 10.1371/journal.pone.0174774
Addict Sci. 2016;2(1):14-21. 76. Blum K, Chen ALC, Thanos PK, et al. Genetic addiction
doi: 10.17756/jrdsas.2016-023 risk score (GARS) ™ , a predictor of vulnerability to opioid
dependence. Front Biosci (Elite Ed). 2018;10(1):175-196.
66. Febo M, Blum K, Badgaiyan RD, et al. Dopamine
homeostasis: Brain functional connectivity in reward doi: 10.2741/e816
deficiency syndrome. Front Biosci (Landmark Ed). 77. Blum K, Gold M, Modestino EJ, et al. Would induction
2017;22(4):669-691. of dopamine homeostasis via coupling genetic addiction
doi: 10.2741/4509 risk score (GARS ® ) and pro-dopamine regulation benefit
benzodiazepine use disorder (BUD)? J Syst Integr Neurosci.
67. Blum K, Liu Y, Wang W, et al. rsfMRI effects of KB220Z™ on 2018;4.
neural pathways in reward circuitry of abstinent genotyped
heroin addicts. Postgrad Med. 2015;127(2):232-241. doi: 10.15761/JSIN.1000196
doi: 10.1080/00325481.2015.994879 78. Blum K, Gondré-Lewis MC, Baron D, et al. Introducing
precision addiction management of reward deficiency
68. Blum K, Baron D. Opioid substitution therapy: Achieving syndrome, the construct that underpins all addictive
harm reduction while searching for a prophylactic solution. behaviors. Front Psychiatry. 2018;9:548.
Curr Pharm Biotechnol. 2019;20(3):180-182.
doi: 10.3389/fpsyt.2018.00548
doi: 10.2174/138920102003190422150527
79. Blum K, Lott L, Siwicki D, et al. Genetic Addiction Risk
69. Blum K, Baron D, Hauser M, et al. Americas’ opioid/ Score (GARS ) as a predictor of substance use disorder:
™
psychostimulant epidemic would benefit from general Identifying predisposition not diagnosis. Curr Trends Med
population early identification of genetic addiction risk
especially in children of alcoholics (COAs). J Syst Integr Diagn Methods. 2018;1(1).
Neurosci. 2019;5(2):1-3. doi: 10.29011/CTMDM-101.100001
70. Downs BW, Blum K, Baron D, et al. Death by opioids: 80. Blum K, Modestino EJ, Badgaiyan RD, et al. Analysis of
Are there non-addictive scientific solutions? J Syst Integr evidence for the combination of pro-dopamine regulator
Neurosci. 2019;5. (KB220PAM) and naltrexone to prevent opioid use disorder
doi: 10.15761/JSIN.1000211 relapse. EC Psychol Psychiatr. 2018;7(8):564-579.
71. Blum K, Febo M, Badgaiyan RD, et al. Common 81. Blum K, Modestino EJ, Gondre-Lewis M, et al. The
™
neurogenetic diagnosis and meso-limbic manipulation benefits of genetic addiction risk score (GARS ) testing
of hypodopaminergic function in reward deficiency in substance use disorder (SUD). Int J Genom Data Min.
syndrome (RDS): Changing the recovery landscape. Curr 2018;2018(1):115.
Neuropharmacol. 2017;15(1):184-194. doi: 10.29014/IJGD-115.000015
doi: 10.2174/1570159x13666160512150918 82. Blum K, Modestino EJ, Neary J, et al. Promoting precision
72. Blum K, Febo M, Fried L, et al. Pro-dopamine addiction management (PAM) to combat the global opioid
regulator - (KB220) to balance brain reward circuitry in crisis. Biomed J Sci Tech Res. 2018;2(2):1-4.
reward deficiency syndrome (RDS). J Reward Defic Syndr doi: 10.26717/BJSTR.2018.02.000738
Addict Sci. 2017;3(1):3-13.
83. Blum K, Baron D, Lott L, et al. In search of reward deficiency
73. Blum K, Gold MS, Jacobs W, et al. Neurogenetics of acute and syndrome (RDS)-free controls: The “Holy Grail” in genetic
chronic opioid/opioid abstinence: treating symptoms and the addiction risk testing. Curr Psychopharmacol. 2020;9(1):7-21.
cause. Front Biosci (Landmark Ed). 2017;22(8):1247-1288.
84. Blum K, Baron D, McLaughlin T, Gold MS. Molecular
doi: 10.2741/4544 neurological correlates of endorphinergic/dopaminergic
74. Baron D, Blum K, Chen A, Gold M, Badgaiyan RD. mechanisms in reward circuitry linked to endorphinergic
Conceptualizing addiction from an osteopathic deficiency syndrome (EDS). J Neurol Sci. 2020;411:116733.

Volume 7 Issue 3 (2024) 16 doi: 10.36922/itps.1918